secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001104659-24-114800
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q3 2024 royalty revenue $60.5M (+6% YoY); net product sales $27.8M; net income $1.2M
--------------------------------------------------------------------------------

- Royalty revenue from GSK $60.5M, up 6% YoY; core royalty platform continued strong performance.
- US net product sales $19.7M (+68% YoY) driven by GIAPREZA $13.1M, XACDURO $4.3M, XERAVA $2.3M.
- Net income $1.2M ($0.02 basic EPS) vs $82.0M ($1.26) in Q3 2023; unfavorable $35.2M fair value change on Armata investment.
- XACDURO nominated for Prix Galien USA Award; zoliflodacin NDA submission expected early 2025.
- Cash and cash equivalents $260.6M; royalty and product sales receivables $91.1M as of Sep 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465924114800/0001104659-24-114800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465924114800/tm2427621d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-114800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer